President Donald Trump is pursuing a healthcare strategy that few before him were willing to attempt: confronting corporate insurers head-on. And if the administration continues on this path, it will result in the 47th president succeeding where his predecessors failed.
Trump recently signed legislation to rein in pharmacy benefit managers, the shadowy middlemen insurers employ to inflate drug prices through a variety of questionable business practices, and the offshoring of pharmacy benefit operations. His Department of Justice is also conducting an investigation of UnitedHealth Group to combat abusive billing practices. Additionally, a March report from the Office of the Inspector General found hundreds of millions of dollars in savings were not passed through to patients or taxpayers, instead retained within the insurer-PBM system
By targeting insurers — the entities that ultimately determine what patients actually pay — these efforts strike at the core of rising healthcare costs.
WHAT DOES TRUMP’S ANTITRUST ENFORCER
Continue reading
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!